Stock comparison
Amneal Pharmaceuticals
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AMRX
Amneal Pharmaceuticals
Market cap
$3.96B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AMRX | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 65C | GMAB |
| Benjamin Graham | 57D | 64C | GMAB |
| Philip Fisher | 63C | 48D | AMRX |
| Peter Lynch | 54C | 25F | AMRX |
| Joel Greenblatt | 31F | 76B | GMAB |
| Charlie Munger | 53D | 68C | GMAB |
| Terry Smith | 42D | 71C | GMAB |
Side-by-side metrics
| Metric | AMRX | GMAB |
|---|---|---|
| Market cap | $3.96B | $16.5B |
| P/E (TTM) | 32.1x | 6.2x |
| EV/EBIT | 14.9x | 12.0x |
| ROIC (TTM) | 12.64% | 43.78% |
| Gross margin | 38.66% | 93.88% |
| Net margin | 4.02% | 18.23% |
| Revenue CAGR 5y | 9.58% | -18.45% |
| EPS CAGR 5y | 34.63% | -23.48% |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AMRX leads on
- EPS CAGR 5y34.63%vs -23.48%+168%
- Revenue CAGR 5y9.58%vs -18.45%+152%
- Debt / Equity-vs 0.1x+100%
GMAB leads on
- P/E (TTM)6.2xvs 32.1x+81%
- Net margin18.23%vs 4.02%+78%
- Market cap$16.5Bvs $3.96B+76%
- ROIC (TTM)43.78%vs 12.64%+71%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.